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Evans A, McCormack DG, Santyr G, Parraga G. Mapping and
quantifying hyperpolarized 3He magnetic resonance imaging apparent diffusion coefficient gradients. J Appl Physiol 105: 693–699, 2008. First published
June 5, 2008; doi:10.1152/japplphysiol.00178.2008.—We measured hyperpolarized 3He magnetic resonance imaging (MRI) apparent diffusion coefficients (ADC) and quantified ADC gradients in each threeby-three voxel region of interest (ROI). Such local ADC gradients can
be represented in vector maps showing the magnitude (ⱍG3⫻3ⱍ) and
direction of ADC gradients, providing a qualitative visualization tool
and quantitative measurement of airway and air space heterogeneity.
Twenty-four subjects (15 male, mean age ⫽ 67 ⫾ 7 yr) with global
initiative for chronic obstructive lung disease (GOLD) stage II (n ⫽ 9,
mean age 68 ⫾ 6 yr), GOLD stage III chronic obstructive pulmonary
disease (COPD; n ⫽ 7, mean age 67 ⫾ 8 yr), and age-matched healthy
volunteers (n ⫽ 8, mean age 67 ⫾ 6 yr) were enrolled based on their
age and spirometry results. Hyperpolarized 3He MRI was performed
on a whole body 3.0 Tesla system. Mean 3He ADC and ADC standard
deviation were calculated for the center coronal slice, and the mean
magnitude and direction of the ADC gradient vectors were calculated
for each three-by-three voxel matrix (ⱍG3⫻3ⱍ). While the 3He ADC
standard deviation was not significantly different, mean ⱍG3⫻3ⱍ was
significantly different between subjects with stage II (0.14 ⫾ 0.03
cm/s) and stage III COPD (0.19 ⫾ 0.03 cm/s; P ⬍ 0.005) and between
healthy subjects (0.12 ⫾ 0.03 cm/s) and those with stage II COPD
(P ⬍ 0.02). The second order statistic ⱍG3⫻3ⱍ may provide a sensitive
measure of ADC heterogeneity for ROI representing 9.4 ⫻ 9.4 ⫻ 30
mm or 2.6 cm3 of lung tissue.

3
HYPERPOLARIZED He magnetic resonance imaging (MRI) has
emerged as a noninvasive imaging method for the evaluation of
the regional distribution of anatomical and functional pulmonary changes associated with chronic obstructive pulmonary
disease (COPD; Refs. 3, 11, 13, 20, 29). In particular, the
measurement of the 3He apparent diffusion coefficient (ADC;
Ref. 29) has been exploited to probe the lung microstructure in
patients with COPD (3, 11, 19, 20, 29) and in ex vivo explanted
lungs (25, 27). Increases in 3He ADC are consistent with
expected increases in acinar size due to destruction of alveoli
accompanying emphysema (19 –21) and have been shown to
correlate with histological measurements of disease (25, 27)
and with age (7). The heterogeneity in values of ADC across
the lung, measured using the ADC standard deviation (SD), has
also been shown to be increased in subjects with COPD (14,
20), suggesting that there is a greater diversity of acinar and

alveolar size in subjects with COPD compared with healthy
volunteers. It is well established that in emphysema tissue
heterogeneities exist (2, 9, 18) and several in vitro studies (4,
17, 24, 30) have shown that changes in tissue structure and
composition are altered in emphysema and that these result in
changes in tissue mechanics. In vivo, emphysematous changes
also result in considerable radiological heterogeneity measurable using X-ray computed tomography (CT; Ref. 18). For
example, areas of low attenuation in X-ray CT images of
emphysematous patients (2) are believed to correspond to a
distribution of regional disease.
One of the drawbacks of using the hyperpolarized whole
lung mean 3He ADC and ADC SD as a measure of lung tissue
differences and heterogeneity is the resultant loss of regional
information. With respect to the changes in ADC measures
across the lung, postural ADC gradients have been reported (8,
23), and we (6) have also previously observed that regional
ADC measures were dependent on disease status and location
in the anterior-posterior as well as superior-inferior direction in
subjects with stage III COPD (1) and healthy volunteers.
Because in this region of interest (ROI) study we observed that
both anatomical location and disease status provided significant
and important contributions to regional ADC, we endeavored to
develop a more sensitive, regional, second order statistic of
ADC. For example, as shown in the schematic in Figure 1, for
the ROI shown in A and B, the calculated ADC SD would be
the same, but differences related to location can be readily
appreciated and measured using a second order statistic. Accordingly, we postulated that a second order statistic of ADC
gradients measured within the smallest ROI possible might
provide an image-based and regional method of differentiating
between healthy subjects and those with moderate and more
severe disease. Moreover, the development of a method that
could map ADC gradients across the lung might provide a
visual tool to help identify both the magnitude and direction of
such gradients, while preserving the regional context of the
information, which is one of the major advantages of in vivo
imaging.
Therefore, the purpose of this study was to develop and
implement a method of mapping the changes in ADC (or ADC
gradients) in the lung in healthy volunteers and subjects with
COPD using a second order statistic and to show such gradients averaged in the slice plane in each and every nine-voxel
ROI (ⱍG3⫻3ⱍ; 9.4 ⫻ 9.4 ⫻ 30 mm tissue) across the lung. We
present the first qualitative examples of such ADC gradient
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Fig. 1. Schematic tissue heterogeneity measurement. Two different regions of
interest are shown in schematic A and B to show how the same apparent
diffusion coefficients (ADC) SD provides different second order statistic or
three-by-three voxel matrix (ⱍG3⫻3ⱍ).

vector maps in a representative healthy subject and representative subjects with global initiative for chronic obstructive
lung disease (GOLD) stage II (or moderate; Ref. 1) and stage
III (or severe) COPD (1). In addition, a quantitative analysis of
ⱍG3⫻3ⱍ for the center coronal slice is provided for 8 healthy
volunteers and 16 subjects with COPD.
METHODS

Research subjects. Subjects were enrolled in this study based on
their age and GOLD criteria (1) classification after providing written
informed consent to the study protocol approved by the University of
Western Ontario Standing Board of Human Research Ethics and
Health Canada, as described previously (6, 16). COPD subjects
required a disease diagnosis of at least 1 yr, having had a smoking
history of at least 10 pack-years and fewer than 3 exacerbations within
the last 12 mo. Healthy subjects were included if they had no history
of chronic respiratory disease, less than one pack-year smoking
history, forced expiratory volume in 1 s (FEV1) ⬎80% predicted,
FEV1 divided by the forced vital capacity (FVC) or FEV1/FVC
⬎70%, and no current diagnosis or history of cardiovascular disease.
Throughout the duration of the study, COPD subjects were to be
withdrawn from the study if they experienced a COPD exacerbation.
COPD subjects were categorized according to the GOLD criteria (1),
based on postbronchodilator FEV1 as moderate or stage II (FEV1
⬎50% and ⬍80% predicted) and severe or stage III (FEV1 ⬎30% and
⬍50% predicted).
Study assessments. After subjects provided written, informed consent, they were screened for MRI and coil compatibility and underwent a physical exam, plethysmography, and spirometry. Spirometry
and plethysmography were performed in the morning after patients
delayed inhaled bronchodilators and corticosteroids for ⬃12 h.
Briefly, spirometry was performed pre- and postbronchodilator using
an ndd EasyOne spirometer (ndd Medizintchnik AG, Zurich, CH)
reporting FEV1 (absolute and percent predicted) and FVC. Whole
body plethysmography (SensorMedics VIASYS Healthcare, Yorba
Linda, CA) was also performed at the pulmonary function laboratory
at University Hospital (London Health Sciences Centre, London,
Canada) for the measurement of total lung capacity, residual volume,
and functional residual capacity.
MRI. MRI was performed on a whole body 3.0 Tesla Excite 12.0
MRS system [General Electric Health Care (GEHC), Durham, NC]
with broadband imaging capability as described previously (6, 16).
All helium imaging used a whole body gradient set with maximum
gradient amplitude of 1.94 G/cm and a single channel, elliptical
transmit/receive chest coil (RAPID Biomedical GmbH, Wuerzburg,
Germany). The basis frequency of the coil was 97.3 MHz, and the
excitation power was 3.2 kW using an AMT 3T90 RF power amplifier
(GEHC). 3He multislice images were obtained in the coronal plane
using a fast gradient-recalled echo method with centric k-space
J Appl Physiol • VOL

sampling. Two interleaved images [echo time (TE) ⫽ 3.7 ms, relaxation time (TR) ⫽ 7.6 ms, 128 ⫻ 128, 7 slices, 30-mm thick, field of
view (FOV) ⫽ 40 ⫻ 40 cm] without and with additional diffusion
sensitization (gradient ⫽ 1.94 G/cm, rise and fall time ⫽ 0.5 ms,
duration ⫽ 0.46 ms, b value ⫽ 1.6 s/cm2) were acquired for each
slice. All scanning was completed within ⬃10 min of subjects first
lying in the scanner. Hyperpolarized 3He gas was provided by a
turn-key, spin-exchange optical pumping system (HeliSpin, GEHC)
as described previously (6, 16). Briefly, in a typical study this system
provided 30% polarization in 12 h. Doses (5 ml/kg) were delivered in
1-liter plastic bags (Tedlar, Jensen Inert Products, Coral Springs, FL)
diluted with ultrahigh purity, medical-grade nitrogen (Spectra Gases,
Alpha, NJ) so that the total volume of gas inhaled for each subject was
1 liter. Polarization of the diluted dose was quantified by a polarimetry
station (GEHC). 3He MR scans were acquired during an inhalation
breathhold after inspiration from a tidal volume of the 1-liter volume
of 3He mixed with N2 (5 ml/kg dose).
Image analysis. 3He MRI images were analyzed by a single
observer and ADC was calculated on a pixel-by-pixel basis with a b
value of 1.6 s/cm2, as described previously (6, 16). To summarize
briefly, all image slices were previously analyzed for ADC (6), but for
this investigation, only the center coronal slice for each individual
subject was assessed, where the center slice image was chosen based
on the location of the carina. After the trachea and major airways were
segmented and removed, the mean ADC and SD of ADC for the entire
slice were calculated. The diffusion-weighted images were analyzed
by a single trained observer in an image visualization environment
(digital copy) with room-lighting levels equivalently established for
all image analysis sessions. Mean ADC and ADC maps were processed using an in-house software programmed in the IDL Virtual
Machine platform (Research Systems, Denver, CO) as described
previously (6, 16).
ADC gradients. A schematic of the methodology developed to
calculate ADC gradient vectors is provided in Fig. 2. To summarize,
the vector gradient (local rate of change in ADC value) as shown in
an ADC map (Fig. 2A) was quantified in a three-by-three voxel-byvoxel ROI (Fig. 2B) and displayed using ADC vector gradient maps
(Fig. 2C). Thus differences in ADC within an ROI were calculated
and expressed as both magnitude and direction of ADC gradient.
Accordingly, in the ADC gradient vector map shown in Fig. 2, vectors
in voxel locations represent both the magnitude and direction of local
ADC gradients for that ROI. A representative calculation is shown in
Fig. 2, where ai,j is the ADC value at location i,j in the image.
The vector gradient in ADC values at i,j is given by:
 i,j ⫽ Gxi,j x̂ ⫹ Gyi,j ŷ
G

(1)

where x and y are unit vectors and Gxi,j and Gyi,j are the average x and
y direction vector components given by:
Gx i,j ⫽

1
关ai⫹1,j⫹1 ⫹ ai⫹1,j ⫹ ai⫹1,j⫺1 ⫺ ai⫺1,j⫹1 ⫺ ai⫺1,j ⫺ ai⫺1,j⫺1兴
6⌬

(2)

1
关ai⫹1,j⫹1 ⫹ ai,j⫹1 ⫹ ai⫺1,j⫹1 ⫺ ai⫹1,j⫺1 ⫺ ai,j⫺1 ⫺ ai⫺1,j⫺1兴
6⌬

(3)

and
Gy i,j ⫽

where the pixel size is ⌬ ⫽ 3 mm in both x and y directions.
The gradient magnitudes and directions are given by:
G i,j ⫽ 冑Gxi,j2 ⫹ Gyi,j2

(4)

and
 ⫽ arctan

Gy
Gx

(5)

A representative “quiver plot” (Matlab 6.5, The Mathworks, Natick,
MA) of ADC vector gradient is shown in Fig. 2C.
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Fig. 2. Schematic of 3He ADC gradient vector methodology. A: ADC map and region of interest from which ADC gradient vectors were calculated.
B: representative region of interest three-by-three voxel matrix from ADC map with resultant calculated vector, Gi,,j, which summarizes magnitude and direction
of ADC gradient. C: resulting ADC vector map corresponding to ADC map in A.

All coronal slices were acquired with 30-mm thickness, and,
therefore, the ADC value in the z direction was accordingly an
average over this 30-mm thick slice. Before the ADC map was
evaluated for the generation of vectors, image noise was filtered (out
of the Bo image) by applying a hanning filter to the k-space data
thereby applying a noise threshold to the resulting image. The hanning
filter is a narrow band filter that helped suppress noise and enhanced
signal in k-space and did not effect the ADC calculation. After the
image noise filter was applied and an ADC map was created, an ADC
map filter was used to create the vector maps. This filter worked by
refusing to calculate an ADC gradient for any three-by-three voxel
ROI where at least one voxel value was ⬍0.05 cm2/s. The value of
0.05 cm2/s was empirically set as a threshold for edge voxels (such as
those on the edge of an unventilated portion of an image), because this
value was two SDs below the mean ADC of healthy subjects.
Therefore, edge voxels were defined as those voxels with a neighboring voxel value ⬍0.05 cm2/s and were not included in the analysis.
Statistical analysis. Mean ⱍGi,jⱍ values for three-by-three voxel
matrices (ⱍG3⫻3ⱍ) were calculated using Matlab 6.5 (Mathworks,
Natick, MA). All statistical analyses were performed using the SPSS
15.0 statistical package (LEAD Technologies, Chicago, IL). Statistical comparisons of mean ADC, SD of ADC, and ⱍG3⫻3ⱍ were
conducted using the one-way ANOVA, and multiple comparisons
between subject subgroups were performed using the Fisher’s least
significant difference test. Levene’s test was used to ensure equality of
variance between groups. In all statistical analyses, results were
considered significant when the probability of making a Type I error
was ⬍5% (P ⬍ 0.05).
RESULTS

Research subjects. Demographic characteristics for all 24
subjects enrolled and evaluated in this study (15 male) are

provided in Table 1 with very similar mean ages and age
ranges for each subgroup. No subjects were withdrawn from
the study due to COPD exacerbations. As the COPD subjects
and healthy volunteers were enrolled based upon FEV1 and
FEV1/FVC according to GOLD criteria (1), the mean values
for FEV1 and FEV1/FVC for each subject subgroup reflect the
GOLD criteria categorization. In addition to the expected and
significantly decreased FEV1 and FEV1/FVC for the COPD
subgroups compared with the healthy volunteers (P ⬍ 0.01),
the baseline functional residual capacity was significantly increased for both COPD subject groups (P ⬍ 0.01) and the total
lung capacity was also significantly increased for the stage III
COPD subgroup only (P ⬍ 0.001), both findings consistent
with lung hyperinflation. Baseline residual volume was also
significantly increased for the stage III COPD subgroup (P ⬍
0.001), which is consistent with gas trapping.
ADC and ADC gradients. Figure 3 shows 3He MR images
(Fig. 3A), corresponding 3He ADC maps (Fig. 3B) and corresponding ADC histograms (Fig. 3C) for three representative
study subjects including a healthy elderly subject (shown in
Fig. 3, A–C, i), a subject with stage II COPD (shown in Fig. 3,
A–C, ii), and a subject with stage III COPD (shown in Fig. 3,
A–C, iii).
Figure 4A shows the results of the calculation of ADC
gradients across each and every contiguous three-by-three or
nine-voxel matrix (9.4 ⫻ 9.4 ⫻ 30 mm) as a 3He MRI ADC
gradient vector map for the same representative subjects shown
in Fig. 3. The magnitude and direction of the ADC gradients
are displayed as yellow vectors that show regional differences

Table 1. Subject demographics

Age, yr (⫾SD)
Male sex
FEV1, % (⫾SD)*
IC, % (⫾SD)*
FRC, % (⫾SD)*
RV, % (⫾SD)*
TLC, % (⫾SD)*

Healthy Volunteers (n ⫽ 8)

Stage II (Moderate) COPD (n ⫽ 9)

Stage III (Severe) COPD (n ⫽ 7)

All Subjects (n ⫽ 24)

67 (6)
5
106 (19)
111 (160)
95 (14)
97 (10)
104 (19)

68 (5)
4
63 (8)
99 (18)
116 (14)
142 (20)
108 (9)

66 (8)
6
42 (7)
78 (17)
152 (37)
188 (55)
115 (23)

67 (7)
15
73 (35)
96 (22)
120 (32)
145 (48)
109 (15)

COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; IC, inspiratory capacity; FRC, functional residual capacity; RV, residual
volume; TLC, total lung capacity. *Predicted.
J Appl Physiol • VOL
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Fig. 3. 3He MRI center coronal slice ADC
analysis. A: 3He MR images of a healthy
volunteer (i), a subject with stage II (moderate) chronic obstructive pulmonary disease
(COPD; ii), and a subject with stage III
(severe) COPD (iii). B: 3He ADC maps of a
healthy volunteer (i), a subject with stage II
(moderate) COPD (ii), and subject with stage
III (severe) COPD (iii). C: 3He ADC histograms of a healthy volunteer (i), a subject
with stage II (moderate) COPD (ii), and a
subject with stage III (severe) COPD (iii).

in local ADC gradients across the center coronal slice.
In Fig. 4B, a histogram analysis of ⱍG3⫻3ⱍ values shown in the
map in Fig. 4A is provided and these show the mean ⱍG3⫻3ⱍ and
ⱍG3⫻3ⱍ SD for each of the representative subjects.

Table 2 provides a summary of the results for all subjects by
subgroup for mean ADC, ADC SD, and mean ⱍG3⫻3ⱍ, ⱍG5⫻5ⱍ, and
ⱍG7⫻7ⱍ. The difference in mean ADC was significantly different
between the subgroup of healthy volunteers and subjects with

Fig. 4. 3He MRI ADC gradient vector maps. A: ADC ⱍG3⫻3ⱍ gradient vector map for a representative healthy volunteer (i), a subject with stage II (moderate)
COPD (ii), and a subject with stage III (severe) COPD (iii). B: ADC ⱍG3⫻3ⱍ gradient vector histograms for a representative healthy volunteer (i), a subject with
stage II (moderate) COPD (ii), and a subject with stage III (severe) COPD (iii).
J Appl Physiol • VOL
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stage II COPD (P ⬍ 0.05) and stage III COPD (P ⬍ 0.01) but not
between the subgroup with stage II and subgroup with stage III
COPD. The ADC SD was also not significantly different between
subject subgroups with stage II and stage III COPD or between
healthy volunteers and subjects with stage II COPD. However, for
mean ⱍG3⫻3ⱍ, there was a statistically significant difference between subjects with stage II (0.14 ⫾ 0.03 cm/s) and stage III
COPD (0.19 ⫾ 0.03 cm/s, P ⬍ 0.005) and between healthy
volunteers (0.12 ⫾ 0.03 cm/s) and subjects with stage II (P ⬍
0.02) and stage III COPD (P ⬍ 0.0001). The results (Table 2) for
ⱍG5⫻5ⱍ and ⱍG7⫻7ⱍ are also similar to those observed for ⱍG3⫻3ⱍ.
Figure 5 provides a direct comparison of mean ADC and mean
ⱍG3⫻3ⱍ for each of the subgroups by subject.
DISCUSSION

A central challenge in our understanding of COPD progression is an in vivo description of how and where specific
changes in airways and air spaces are occurring over time.
While COPD is recognized as a heterogeneous lung disease
(18), it is typically diagnosed on the basis of global lung
function, such as spirometry and diffusing capacity for carbon
monoxide, and, less routinely, lung tissue destruction is measured as low attenuation areas using X-ray CT (2, 12, 22, 26).
The hyperpolarized 3He MRI ADC has been shown to correlate
with histological measurements of emphysematous disease
(25, 28) ex vivo. As the 3He ADC provides an average value
for the subvoxel contributions of both airways and air spaces to
3
He diffusion, we hypothesized that a regional second order
statistic of ADC could be developed to provide an in vivo
measurement of regional heterogeneity of disease. In addition,
we postulated that such 3He ADC gradients could provide a
novel in vivo filter capable of discriminating between COPD
subgroups with different disease severities. Accordingly, our
goal was to develop an in vivo measure of regional lung
disease heterogeneity in COPD patients, based on the measurement of the 3He ADC using hyperpolarized 3He MRI. Toward
achieving this goal, we present 1) the development of an ADC
gradient vector mapping method based on a nine-voxel average
(9.4 ⫻ 9.4 ⫻ 30 mm), 2) the application of this mapping
method to qualitatively display regional ADC heterogeneity in
elderly healthy volunteers and subjects with COPD, and 3)
calculation of a quantitative second order statistic, (ⱍG3⫻3ⱍ),
that provides the mean of such gradients averaged over each
and every nine-voxel ROI across the lung.
The ADC gradient maps depicting vector gradients for
nine-voxel ROI provide a qualitative determination of airway
and air space heterogeneity in small ROI that correspond to 2.6
cm3 of lung tissue. A design-based stereological approach (15)

Fig. 5. Mean 3He ADC and mean ⱍG3⫻3ⱍ for all subjects by subgroup. Mean
ADC and ⱍG3⫻3ⱍ by subject subgroup. Subjects with stage III (severe) COPD
statistically significantly different than subjects with stage II (moderate) COPD
(P ⬍ 0.005) and healthy volunteers (P ⬍ 0.0001).

recently estimated the mean size of a single normal alveolus to
be 4.2 ⫻ 10⫺6 cm3 irrespective of lung size. According to these
calculations, the ADC gradients calculated here correspond to
the contributions of ⬃500,000 – 600,000 alveoli within the
2.6-cm3 voxel matrix. The gradient maps provide a visual
snapshot of the heterogeneity of the contributing alveoli and
airways to the calculated ADC using the ⱍG3⫻3ⱍ filter. These
maps also provide the ability to determine qualitative differences between subjects and within the lung of individual
subjects. The ADC ⱍG3⫻3ⱍ shown in Fig. 4 and summarized in
Table 2 also provides a new second order statistic that describes the mean magnitude of the ADC gradients within the
2.6-cm3 voxel, which like the ADC SD, provides a measure of
ADC heterogeneity. However, as shown in Table 2, ⱍG3⫻3ⱍ is
significantly different between stage II COPD and stage III
COPD (P ⬍ 0.005), unlike SD of ADC, which is not significantly different between COPD subgroups. The preservation of
regional context in ⱍG3⫻3ⱍ may have resulted in this difference
in sensitivity between ADC SD and ADC ⱍG3⫻3ⱍ observed.
Previous to this work, the age dependence (7) and anatomical dependence (6, 8, 23) of the 3He ADC has been shown.
The finding here of significantly different ADC gradients in 2.6
cm3 voxels in stage II and stage III COPD subjects suggests
that aggressive destruction of parenchyma is regionally more
heterogeneous as disease severity (measured using spirometry)
increases.

Table 2. 3He ADC gradients
Significance of Difference (P Value)

2

Mean ADC, cm /s (⫾SD)*
SD ADC, cm2/s (⫾SD)*
ⱍG3⫻3ⱍ, cm/s (⫾SD)*
ⱍG5⫻5ⱍ, cm/s (⫾SD)*
ⱍG7⫻7ⱍ, cm/s (⫾SD)*

Healthy Volunteers (n ⫽ 8)

Stage II (Moderate) COPD (n ⫽9)

Stage III (Severe) COPD (n ⫽ 7)

HV-M

HV-S

M-S

0.25 (0.02)
0.18 (0.02)
0.12 (0.03)
0.12 (0.03)
0.12 (0.03)

0.37 (0.1)
0.22 (0.08)
0.14 (0.03)
0.15 (0.06)
0.16 (0.06)

0.42 (0.1)
0.26 (0.09)
0.19 (0.03)
0.18 (0.03)
0.20 (0.06)

P ⬍ 0.05
P ⬎ 0.1
P ⬍ 0.02
P ⬍ 0.003
P ⬍ 0.02

P ⬍ 0.01
P ⬍ 0.01
P ⬍ 0.0001
P ⬍ 0.0001
P ⬍ 0.0001

P ⬎ 0.2
P ⬎ 0.1
P ⬍ 0.005
P ⫽ 0.05
P ⬍ 0.005

*Bracketed values are SD of the mean for the subgroup. HV, healthy volunteers; M, subjects with stage II (moderate) COPD; S, subjects with Stage III (severe)
COPD.
J Appl Physiol • VOL
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One of the limitations of this study includes the small group
of subjects in which we piloted this approach. The large-scale
application of this method to a larger group of healthy volunteers of various ages and those with stage I COPD will be
required to assess ⱍG3⫻3ⱍ differences within subjects with less
severe and no apparent disease and to visualize and quantify
gradients over time as disease progresses. An important consideration to note is that the method of deriving ADC ⱍG3⫻3ⱍ
developed in this study uses rather thick slices generated by
diffusion-weighted imaging (30 mm), which results in ⱍG3⫻3ⱍ
reflecting a rather large (9.1 ⫻ 9.1 ⫻ 30 mm) anisotropic
voxel. The filter provided by ⱍG3⫻3ⱍ enables a measurement of
heterogeneity within the voxel measured and across the lung
slice; however, three-dimensional imaging approaches with
thinner slices would allow for the determination of heterogeneity in smaller and less anisotropic voxels, perhaps yielding
even more information and with greater sensitivity. In other
words, thinner slices would allow for the derivation of smaller
filters to discern potential heterogeneity differences within
smaller ROI. We note that we also determined ADC ⱍG5⫻5ⱍ,
ⱍG7⫻7ⱍ, and ⱍG9⫻9ⱍ and observed the same mean values for the
subgroups as were determined for ⱍG3⫻3ⱍ. This result suggests
that smaller filter sizes may provide greater sensitivity to
differences in these subgroups.
One of the original rationales for deriving ⱍG3⫻3ⱍ was to
assess ADC gradients around the perimeter of ventilation
defects as a way to measure lung structural heterogeneity near
areas of the lung that are unable participate in ventilation
within the timeframe of MR image acquisition (14 –16 s). The
derivation of ⱍG3⫻3ⱍ from images acquired with thinner slices
and smaller voxels may help in this regard. The issue of
unventilated or less ventilated lungs within the timeframe of
MR image acquisition leads to the description of a major
fundamental limitation of the approach developed here, which
relates to the fact that the measurement of ADC and ADC
gradients is dependent on the ADC signal from a well-ventilated lung. Hence, ADC ⱍG3⫻3ⱍ ignores the contributions of
those areas of the lung that are unable to participate in ventilation due to bullous disease, mucous plugs, or airway narrowing or collapse. Thus this approach can only reflect heterogeneity in areas of the lung that still participate in ventilation
which provides a distinct bias to the results. In this regard, an
important next step will be to assess correlations between
ⱍG3⫻3ⱍ from MRI and quantitative CT as well as histological
sections.
There is evidence from animal models (10) and from patient
studies (5) suggesting that emphysematous destruction results
in increased SD and coefficients of variation of alveolar diameters and area over time: both suggestive of increased heterogeneity of alveolar size as the disease progresses. The ability,
provided by hyperpolarized 3He MRI, to quantitatively and
noninvasively measure the extent, location, and localized gradients in emphysema has the potential to provide important
physiological information in individual COPD subjects and
subgroups for 1) earlier detection of disease changes and
mapping of changes that accompany disease progression,
2) identification of regional changes after pharmaceutical intervention, and 3) identification of localized disease extent and
severity before and as a way to plan for radiation, pharmaceutical, surgical, and bronchoscopic interventions. In this regard,
the second order statistic we describe here provides a way to
J Appl Physiol • VOL

sensitively and quantitatively measure localized ADC gradients, while preserving the regional information provided by
imaging. We are currently evaluating the use of this measurement in the longitudinal assessment of COPD subjects, which
will provide critical information regarding potential changes in
such gradients in individual subjects and subject subgroups
over time. Our working hypothesis based on the current results
is that subjects with stage II and stage III COPD (who have
stopped smoking) will show increased ⱍG3⫻3ⱍ over relatively
short periods of time (1–2 yr) without changes in spirometric
measurements of disease. We are also directly applying this
method to data sets acquired with thin slices to assess regional
heterogeneity around large ventilation defects with comparison
to CT.
In summary, the ADC gradient maps provide a way to
qualitatively visualize ADC heterogeneity, providing a new
way to evaluate the temporal and spatial dynamics of emphysema within the lung using 3He MRI. Visualization of the
quantitative vectors helps identify both the magnitude and
direction of such gradients, while preserving regional context.
As a first step in the development and application of this
method, qualitative representative examples of such ADC
gradient vector maps in a healthy subject and subjects with
stage II and stage III COPD are provided. In addition, a
quantitative analysis of the mean magnitude of ⱍG3⫻3ⱍ is
provided for 8 healthy volunteers and 16 subjects with COPD,
which provided a means of differentiating subjects with stage
III and stage II COPD. The method evaluated in this study may
provide a means of tracking changes in emphysema over time
in vivo, which can complement (and are certainly more practicable in patients than) histological studies.
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